Objective? To study the clinical application of bubphthalide injection combined with atorvastatin in the treatment of acute progressive cerebral infarction. Methods? A total of 100 patients with acute progressive cerebral infarction admitted to Changzhou Wujin People's Hospital Affiliated to Jiangsu University from February 2018 to January 2020 were selected as the research objects，and were divided into a control group and a experimental group by random number table method，with 50 patients in each group. The control group was treated with atorvastatin calcium tablets，the patients in the experimental group were treated with buphthalein chloride injection on the basis of the treatment of the control group，and the two groups were treated for 14 days. The clinical efficacy of the two groups was compared. The NIHSS score，BI index，the levels of APTT，PT and FIB were compared before and after treatment，and the incidence of adverse reactions was observed. Results? The total effective rate of clinical treatment in the experimental group was 94.00%，significantly higher than that in the control group（80.00%）. The NIHSS score and serum FIB level of the two groups after treatment were both lower than that before treatment，and the experimental group was lower than the control group. The BI index，serum APTT and PT levels after treatment were higher than those before treatment，and the values of the experimental group were higher than those of the control group. After treatment，the incidence of adverse reactions such as nausea，fever and head discomfort in the experimental group was 8.00%，significantly lower than that in the control group 26.00%，with statistically significant differences between groups（P＜0.05）. Conclusion? The combination of bubphthalide injection and atorvastatin in the treatment of acute progressive cerebral infarction can significantly improve the clinical efficacy，improve the function of nerve and coagulation，and effectively reduce the incidence of adverse reactions，clinical application is safe and effective.